Ligand Pharmaceuticals Incorporated (LGNDV) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ligand Pharmaceuticals Incorporated (LGNDV) trades at $50.00. Ligand Pharmaceuticals Incorporated focuses on developing and acquiring technologies to aid pharmaceutical companies in discovering and developing medicines globally. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for LGNDV: LGNDV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LGNDV against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on LGNDV.
How is this calculated? →Ligand Pharmaceuticals Incorporated (LGNDV) Healthcare & Pipeline Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical firm, specializes in enabling drug discovery and development through its diverse technology platforms and strategic partnerships. With a focus on royalty-generating assets and collaborations, Ligand supports a broad portfolio of therapies across multiple disease areas, positioning it as a key player in the biotechnology sector.
What Is the Investment Thesis for LGNDV?
Ligand Pharmaceuticals presents a compelling investment thesis based on its royalty-driven business model and diverse portfolio of partnered programs. The company's strategy of acquiring and licensing enabling technologies provides a diversified revenue stream with reduced development risk compared to traditional pharmaceutical companies. Key value drivers include the continued success of partnered drugs like Kyprolis and Veklury, as well as the advancement of clinical-stage programs. Growth catalysts include potential new drug approvals and expanded indications for existing therapies. The company's high gross margin of 97.5% reflects the profitability of its royalty-based model. However, potential risks include reliance on partners' success and regulatory hurdles for new drug approvals. The P/E ratio of 33.44 suggests a premium valuation, reflecting investor expectations for future growth.
Based on FMP financials and quantitative analysis
LGNDV Key Highlights
Gross Margin of 97.5% showcases the profitability of Ligand's royalty-based business model.
- Profit Margin of 46.4% indicates efficient operations and strong earnings potential.
- P/E Ratio of 33.44 reflects investor expectations for future growth and earnings.
- Beta of 1.07 suggests the stock's volatility is similar to the overall market.
- Ligand's diverse portfolio of partnered programs reduces the risk associated with individual drug development.
Who Are LGNDV's Competitors?
LGNDV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LGNDV's Key Strengths?
Proprietary enabling technologies like Captisol.
- Diversified revenue streams through royalties and milestone payments.
- Established partnerships with major pharmaceutical companies.
- High gross margin due to royalty-based business model.
What Are LGNDV's Weaknesses?
Reliance on partners' success in drug development and commercialization.
- Potential impact from generic competition to partnered drugs.
- Dependence on regulatory approvals for new drugs and expanded indications.
- Limited control over partners' marketing and sales efforts.
What Could Drive LGNDV Stock Higher?
Continued sales growth of partnered drugs like Kyprolis and Veklury.
- Potential regulatory approvals for partnered drugs in clinical development.
- Expansion of Captisol utilization in new drug formulations.
- Strategic acquisitions of complementary technologies and partnerships.
What Are the Key Risks for LGNDV?
Regulatory hurdles and delays in drug approvals.
- Reliance on partners' success in drug development and commercialization.
- Patent expirations and generic entry of partnered drugs.
- Changes in healthcare policies and reimbursement rates.
What Are the Growth Opportunities for LGNDV?
- Expansion of Captisol Utilization: Captisol, Ligand's proprietary technology, enhances the solubility and stability of drugs. Expanding its use in new formulations and therapeutic areas presents a significant growth opportunity. The market for drug solubilization technologies is projected to reach $5 billion by 2028, driven by the increasing complexity of drug molecules. Ligand can leverage its established reputation and technical expertise to capture a larger share of this market.
- Advancement of Clinical-Stage Programs: Ligand has numerous partnered programs in clinical development, targeting various diseases. Successful clinical trials and subsequent regulatory approvals represent significant growth catalysts. The global market for cancer therapies, for example, is expected to reach $200 billion by 2027. Ligand's partners are actively pursuing approvals in oncology, immunology, and other therapeutic areas, offering substantial revenue potential.
- Strategic Acquisitions and Partnerships: Ligand can drive growth through strategic acquisitions of complementary technologies and partnerships with pharmaceutical companies. This allows the company to expand its portfolio of enabling technologies and access new markets. The market for biotechnology acquisitions remains active, with numerous opportunities to acquire innovative technologies and expand market reach. Ligand's strong financial position enables it to pursue such opportunities.
- Geographic Expansion: Ligand primarily operates in North America and Europe. Expanding its presence in emerging markets, such as Asia-Pacific and Latin America, presents a significant growth opportunity. These regions are experiencing rapid growth in healthcare spending and increasing demand for innovative therapies. Ligand can leverage its existing partnerships and establish new collaborations to penetrate these markets.
- Development of New Enabling Technologies: Investing in the development of new enabling technologies can create new revenue streams and strengthen Ligand's competitive position. This includes technologies related to drug delivery, formulation, and manufacturing. The market for innovative drug delivery systems is projected to reach $80 billion by 2026, driven by the need for more effective and patient-friendly therapies. Ligand's expertise in chemistry and formulation positions it well to capitalize on this trend.
What Are LGNDV's Competitive Advantages?
- Proprietary Technologies: Ligand's Captisol technology and other enabling technologies provide a competitive advantage.
- Royalty-Based Business Model: The royalty-based model provides a diversified revenue stream with reduced development risk.
- Established Partnerships: Ligand has established long-term partnerships with numerous pharmaceutical companies.
- Diversified Portfolio: The company's diverse portfolio of partnered programs reduces reliance on individual drugs.
What Does LGNDV Do?
Ligand Pharmaceuticals Incorporated, established in 1987 and headquartered in San Diego, California, operates as a biopharmaceutical company dedicated to the development and acquisition of technologies that facilitate drug discovery and development for pharmaceutical companies worldwide. The company's business model revolves around creating or acquiring enabling technologies that are then licensed to partners, generating revenue through royalties, milestone payments, and material sales. Ligand's commercial programs feature a diverse range of therapies, including Kyprolis and Evomela for multiple myeloma, Veklury for COVID-19, and Teriparatide injection for osteoporosis. Other key products include Vaxneuvance and Pneumosil vaccines, Rylaze for acute lymphoblastic leukemia, Nexterone, Zulresso, Noxafil-IV, and Duavee for postmenopausal osteoporosis. Additionally, Ligand offers the Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products, along with treatments for autoimmune diseases, breast cancer, hypertension, and other conditions. The company also sells Captisol materials, a chemically modified cyclodextrin used to improve the solubility and stability of drugs. Ligand's strategy focuses on acquiring and developing technologies that can be broadly applied across the pharmaceutical industry, creating a diversified revenue stream and reducing the risks associated with individual drug development programs. This approach has allowed Ligand to establish partnerships with numerous pharmaceutical companies, contributing to the development of a wide range of therapies.
What Products and Services Does LGNDV Offer?
- Develops and acquires technologies to aid pharmaceutical companies in drug discovery.
- Licenses its technologies to partners, generating revenue through royalties and milestone payments.
- Sells Captisol materials, a chemically modified cyclodextrin used to improve drug solubility.
- Supports a broad portfolio of therapies across multiple disease areas.
- Focuses on royalty-generating assets and strategic collaborations.
- Provides enabling technologies for drug formulation and delivery.
How Does LGNDV Make Money?
- Ligand generates revenue primarily through royalties on sales of partnered drugs.
- The company also receives milestone payments upon achievement of specific development or regulatory milestones.
- Ligand sells Captisol materials to pharmaceutical companies for use in drug formulations.
What Industry Does LGNDV Operate In?
Ligand Pharmaceuticals operates within the biotechnology industry, a sector characterized by rapid innovation, high R&D spending, and significant regulatory oversight. The market is driven by the increasing demand for novel therapies to address unmet medical needs. Ligand's unique business model, focused on enabling technologies and royalty streams, differentiates it from traditional pharmaceutical companies that bear the full risk of drug development. The competitive landscape includes companies offering similar enabling technologies and contract research organizations (CROs). The biotechnology industry is projected to continue growing, driven by advancements in genomics, personalized medicine, and biomanufacturing.
Who Are LGNDV's Key Customers?
- Pharmaceutical companies developing new drugs.
- Biotechnology companies seeking enabling technologies.
- Contract research organizations (CROs) involved in drug development.
Company Profile
Ligand Pharmaceuticals Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO John L. Higgins. LGNDV has traded publicly since 2022.
Key Financial Metrics
Return on equity for Ligand Pharmaceuticals Incorporated stands at 16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.0%, showing how much profit it generates from its asset base. LGNDV trades at a trailing price-to-earnings ratio of 40.89, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.4%, the inverse of the P/E and a quick read on earnings relative to price.
LGNDV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity suggests confidence from those closest to the company, potentially signaling undervalued prospects.
- Community sentiment indicates a growing belief in the company's long-term strategy and pipeline, fostering a positive outlook.
- The market perceives the company as a key player in its niche, with potential for partnerships and acquisitions boosting its profile.
- Bullish community views highlight the company's innovative approach and potential to disrupt the market, attracting more investors.
Bear Case
- Recent insider selling, although potentially for personal reasons, raises concerns about short-term performance among some investors.
- Bearish community views express worries over increasing competition and potential challenges in securing future deals.
- Community sentiment reveals uncertainties surrounding the regulatory landscape and its potential impact on the company's pipeline.
- Market perception suggests the company's valuation may be stretched, making it vulnerable to market corrections or negative news.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LGNDV Latest News
No recent news available for LGNDV.
LGNDV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LGNDV.
Price Targets
Wall Street price target analysis for LGNDV.
LGNDV MoonshotScore
What does this score mean?
The MoonshotScore rates LGNDV 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John L. Higgins
Unknown
Information about John L. Higgins's background is not available in the provided context. Therefore, a detailed biography including his career history, education, and previous roles cannot be provided. Further research would be needed to gather this information and provide a comprehensive profile.
Track Record: Due to the lack of available information regarding John L. Higgins's background and tenure, it is not possible to provide details on his key achievements, strategic decisions, or company milestones under his leadership. Additional research is necessary to assess his track record and contributions to Ligand Pharmaceuticals Incorporated.
What Investors Ask About Ligand Pharmaceuticals Incorporated (LGNDV) — Healthcare
What does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical company focused on enabling drug discovery and development for pharmaceutical companies globally. Its business model centers around developing or acquiring technologies that enhance drug properties, such as solubility and stability, and then licensing these technologies to partners.
What are the main risks for LGNDV?
Ligand Pharmaceuticals Incorporated faces several key risks inherent in the biotechnology industry. A primary risk is the reliance on partners' success in drug development and commercialization, as Ligand's revenue is largely dependent on royalties from partnered drugs. Regulatory hurdles and potential delays in drug approvals also pose a significant risk.
What are the key factors to evaluate for LGNDV?
Evaluate LGNDV on fundamentals, analyst consensus, and risk factors. Ligand Pharmaceuticals presents a compelling investment thesis based on its royalty-driven business model and diverse portfolio of partnered programs. Not financial advice.
How frequently does LGNDV data refresh on this page?
LGNDV's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LGNDV's recent stock price performance?
Ligand Pharmaceuticals Incorporated (LGNDV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary enabling technologies like Captisol. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LGNDV overvalued or undervalued right now?
Ligand Pharmaceuticals Incorporated (LGNDV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LGNDV before investing?
Before investing in Ligand Pharmaceuticals Incorporated (LGNDV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LGNDV to a portfolio?
Key strength of Ligand Pharmaceuticals Incorporated (LGNDV): Proprietary enabling technologies like Captisol. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided sources and may not be exhaustive.
- Analyst consensus and competitor data are limited.